

A Comparative Study of Some Functional Properties of *Lactobacillus* and *Enterococcus* Isolated from Feces of Normo and Hyper-Cholesterolemic Humans

María de Lourdes Reyes-Escogido^{1*}, Claudia Mercedes Gómez-Navarro¹, Silvia Daniela Ramírez-Ardila², Francisco Martínez-Pérez², Rodolfo Guardado-Mendoza²

¹Departamento de Medicina y Nutrición, División de Ciencias de la Salud, Universidad de Guanajuato, Blvd. Puente del Milenio 1001, Fracción Predio de San Carlos, León, Guanajuato, México

²Laboratorio de Genómica de Celomados Grupo Microbiología y Genética, Facultad de Ciencias y Grupo de Investigación de Inmunología y Epidemiología Molecular, Facultad de Salud, Universidad Industrial de Santander, Bucaramanga, Santander, Colombia

Abstract

There have been reports of an association between an imbalance of gastrointestinal microbiota and several kinds of diseases, mainly metabolic diseases. *Lactobacillus* and *Enterococcus* are two genera that form part of the native gastrointestinal microbiota. In this work, we isolated, identified and characterized 26 strains of *Lactobacillus* and 23 strains of *Enterococcus* from the feces of normo and hypercholesterolemic humans. We compared the behavior exhibited by all strains at acid pH and in presence of bile salts, their sensitivity to antibiotics, and their ability to hydrolyze bile salts and to reduce cholesterol *in vitro*. The highest percentage of all isolated and characterized *Lactobacillus* strains was from the normocholesterolemic group; in the hypercholesterolemic group, most strains belonged to the *Enterococcus* genus. The *Lactobacillus* strains showed greater capacity to reduce cholesterol levels; although this capacity has been related to bile salt hydrolase activity, four of the strains we isolated showed no such activity, but still reduced cholesterol. All strains of both genera isolated from normocholesterolemic participants showed a highest rate of cholesterol reduction than those isolated from hypercholesterolemic participants. Furthermore, the *Lactobacillus* strains showed greater resistance at pH 2.0, while strains of both genera showed similar survival rates at pH 3.0 and in the presence of bile salts after 24 h. These results support the evidence that a microbial imbalance involving the depletion of beneficial bacteria could be detrimental to the health of the host.

Keywords: *Enterococcus*; Gastrointestinal microbiota; Hypocholesterolemic activity; *Lactobacillus*

Introduction

The human gastrointestinal tract (GIT) is colonized by a diverse and complex collection of bacterial species; it is estimated that the colon contains around 70% of all the microorganisms in the human body [1], forming a balanced and dynamic ecosystem that plays an important role in various human body functions. An imbalance in the composition of intestinal bacteria is associated with a variety of diseases such as dysbiosis, colon cancer and hypercholesterolemia, among others [2]. The gastrointestinal tract contains native microorganisms that positively influence health. The majority of these microorganisms belong to the group of lactic acid bacteria (BAL) that includes the bacterial genera *Streptococcus*, *Enterococcus*, *Leuconostoc*, *Pediococcus*, *Lactococcus*, *Lactobacillus* and others within the order of Lactobacillales, such as the genus *Bifidobacterium* [3]. At the beginning of the 20th century, Ely Metchnikoff proposed various theories about the positive health effects of the consumption of *Lactobacillus*; these theories are still accepted and have contributed to the conviction that these bacteria perform a very important function. A study by Marreau et al. 2001 reported that *Lactobacillus-Enterococcus* comprise 6.6% of the bacterial population in feces [4]. It has also been reported that *Enterococcus*, which has been part of gut microbiomes since at least the early Devonian period, comprises a little less than 1% of the human gastrointestinal microbiota [5]. Although various strains of this genus have been associated with infections, others have been found to have beneficial health effects on the host, and have even been used as probiotics [6]; however, the probiotic effects of this genus have been little studied compared to *Lactobacillus*. *In vivo* and *in vitro* studies of various strains of both genera have shown their potential to reduce cholesterol, alone or in combination with other strains [7]. Various mechanisms have been

proposed to explain this beneficial activity, all of them associated with the metabolism of the bacteria, such as hydrolase secretion, which has been related to the removal of cholesterol through the hydrolysis of amide bonds and the releases of bile salts [8], since poorly water soluble bile salts precipitate at low pH, and this is related to the co-precipitation of cholesterol; however, not all the cholesterol precipitates, and a part of it may remain bound to the surface of the bacterial cell [9]. Other mechanisms involve the conversion of cholesterol to coprostanol in the intestine, which is later excreted in the feces, reducing the quantity of cholesterol available to be absorbed by the intestine [10]. Cholesterol can also be used as a substrate for the synthesis of new bile acids in a homeostatic response, resulting in the reduction of steric cholesterol [11]. However, most of the information about these mechanisms corresponds to strains of *Lactobacillus* and *Bifidobacterium*, while there is little information regarding the cholesterol reducing capacity of *Enterococcus* strains and the mechanisms involved [12,13]. It is important to study the behavior of strains native to the gastrointestinal tract in order to establish preventive strategies for hyper-cholesterolemia

***Corresponding author:** María de Lourdes Reyes-Escogido, Departamento de Medicina y Nutrición, División de Ciencias de la Salud, Universidad de Guanajuato, Blvd. Puente del Milenio 1001, Fracción Predio de San Carlos, León, Guanajuato, CP. 37670, México. Tel: (+52) 477-2674900 ext. 3683; E-mail: ml.reyes@ugto.mx

Received March 21, 2016; Accepted May 06, 2016; Published May 10, 2016

Citation: Reyes-Escogido ML, Gómez-Navarro CM, Ramírez-Ardila SD, Martínez-Pérez F, Guardado-Mendoza R (2016) A Comparative Study of Some Functional Properties of *Lactobacillus* and *Enterococcus* Isolated from Feces of Normo and Hyper-Cholesterolemic Humans. J Bacteriol Parasitol 7: 274. doi: [10.4172/2155-9597.1000274](https://doi.org/10.4172/2155-9597.1000274)

Copyright: © 2016 Reyes-Escogido ML, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and associated diseases. Statins are generally the most effective drug for controlling high cholesterol levels and preventing disorders related to atherosclerosis [14]; however, although recent studies have shown an increase in the number of patients who consume statins, the number of cases of intolerance or lack of response to statins has also increased [15]. Moreover, statins have been recently considered as a risk factor in the development of liver cancer [16]. The high cost of the drugs, as well as the little willingness to follow a diet and exercise plan, are limiting factors for the effectiveness of pharmacological therapy, which is why the manipulation of the intestinal microbiota has been considered as a good alternative for cholesterol control. It is therefore necessary to study the functional capacity of the native microbiota and its potential contribution to human health.

Material and Methods

Participants

A total of 65 adult volunteers participated in the study; the age range was 18-58 years. We determined the general characteristics of the participants, such as age, sex, body mass index, physical activity, and nutrient consumption; we also determined their glucose and blood cholesterol levels. The participants were asked to avoid consuming fermented foods for at least one week prior to the collection of the fecal sample and isolation of bacteria; they were also asked not to take any antibiotics or anti-inflammatory drugs for one month prior to the study, and to confirm that they did not suffer from any gastrointestinal condition. This study was conducted following the Guidelines for Good Clinical Practice and the Helsinki declaration; informed consent was obtained from all individual participants included in the study.

Nutritional and physical activity assessment

A previously validated semi-quantitative food frequency questionnaire (FFQ) was used to evaluate dietary intake. This questionnaire included data regarding the consumption of 116 food items. A commonly used portion size was specified for each food (e.g. 1 slice of bread or 1 cup of coffee) in the FFQ and the participants reported their frequency of consumption of each food over the previous year. The participants chose from 10 possible responses, ranging from “never” to “6 or more times per day.” For our analysis, the reported frequency for each food item was converted into daily intake values. Total energy intake was computed by summing the energy intake from all foods. The PA level of the participants was assessed using a validated Spanish version of a self-administered questionnaire [17] adapted for use in the Mexican population.

Isolation of lactic acid bacteria

Serial dilution techniques were used to isolate the bacteria. Each sample suspension was prepared by adding 1 g of feces to 9 ml of peptone water; the fecal matter was then suspended by vigorous stirring in a vortex for at least 1 min. Serial dilutions were conducted to obtain concentrations of 10^{-4} and 10^{-5} , which were spread on MRS agar plates; the plates were then incubated at 37°C for 48-72 h in anaerobiosis. After the growth of microorganisms, pure cultures of bacteria were subcultured in MRS agar and incubated at 37°C to promote vigorous growth. We observed the appearance of colonial growth, the reaction to the Gram stain and the microscopic cellular morphology; we confirmed the absence of spores by staining with malachite and through the use of standard biochemical tests (oxidase and catalase).

Susceptibility to antibiotics

We used the disc diffusion method to evaluate the behavior of the

studied strains in the presence of the following antibiotics: Ampicillin (10 µg), Gentamicin (10 µg), Kanamycin (30 µg), Erythromycin (15 µg), Clindamycin (2 µg), Tetracycline (30 µg), Chloramphenicol (30 µg), Streptomycin (10 µg), and Neomycin (30 µg). The concentrations of each antibiotic were determined according to the guidelines of the Clinical and Laboratory Standards Institute [18]. The turbidity of cultures after 24 h of incubation was adjusted to obtain a concentration of 1.5×10^8 UFC ml⁻¹ on the McFarland scale. After adjusting the concentrations, the MRS agar plates were inoculated with the bacteria and the antibiotic discs were placed on each plate. After 20 h of incubation, the halos of inhibition were measured and reported in mm. The results were interpreted as Sensitive (S), Intermediate Sensitivity (I) or Resistant (R) [18].

Tolerance to acid pH and bile salts (0.3% w/v)

Three different types of MRS broth were prepared; two with 6M HCl, one adjusted at pH 2.0 and the other at pH 3.0; the third had MRS and bile salts (0.3% w/v) and was adjusted at pH 6.5. Fresh cultures of each strain were used to inoculate each of the three broths mentioned above, using normal MRS broth as control. The inoculated media were incubated at 37°C in anaerobiosis; aliquots were taken at specific time intervals to inoculate MRS agar plates. From cultures at pH 2.0, aliquots were taken at 0, 0.5, 1.5, 3, and 24 h; from the cultures at pH 3.0 and cultures with bile salts (3.0%), aliquots were taken at 0, 3, and 24 h. All control strains were inoculated at the same time. The inoculated plates were incubated at 37°C for 24 h in anaerobiosis. The survival rate in each type of broth was calculated as the base 10 logarithm of UFC ml⁻¹ and reported as percentage [19].

Hydrolase activity (Bile salt hydrolysis)

We determined the bile salt hydrolase activity (BSH) of the strains using MRS agar supplemented with sodium thioglycolate (0.2%) and taurocholic acid (0.2%). To do this, assay filter paper discs (6 mm in diameter) were inoculated with fresh culture of the corresponding strains. The disks were placed on the MRS agar plates supplemented with bile salts; the plates were then incubated at 37°C for 20-24 h in anaerobiosis. Hydrolase activity was reported as positive when a precipitate was observed in the middle and around the inoculated discs. The precipitate was cholic acid generated by the enzyme.

In vitro cholesterol reduction

We prepared MRS broth supplemented with cholesterol at a final concentration of 100 µg ml⁻¹. This medium was inoculated with 1% of fresh culture of each strain; the inoculums were incubated at 37°C for 20 h in anaerobiosis. Uninoculated sterile broth was also analyzed as negative control. After the incubation period, the cells were removed from the medium by centrifugation (10,000 × g for 15 min), and the supernatant was recovered to determine residual cholesterol using a colorimetric method. The percentage of cholesterol reduction was calculated using the following formula:

$$\% \text{Reduction} = 100 - \frac{B}{C} \cdot 100$$

Where, B: Absorbance of MRS-cholesterol from removed cells; C: Absorbance of MRS-cholesterol from uninoculated broth.

Molecular identification

The extraction of genomic DNA was performed from pure cultures after 24 h of incubation, using a commercial kit (Purelink genomic DNA Kit, Invitrogen, CA, USA). The extracted DNA was used as a template for the partial amplification of the 16S rRNA gene using the

primers forward 5'-AGAGTTTGATCCTGGCTCAG-3' and reverse 5'-AAGGAGGTGATCCAGCCGCA-3' [20]. The PCR products were visualized on agarose gels stained with Ethidium bromide (0.5 µg ml⁻¹). The PCR products were purified using a commercial kit (PureLink PCR purification kit, Invitrogen, CA, USA) and then sent to the IPICYT, A.C. San Luis Potosi, Mexico, for sequencing. The sequence analysis was carried out using the Basic Local Alignment Search Tools (BLAST) from the database of the National Center for Biotechnology Information (NCBI).

Statistical analysis

All experiments were performed in triplicate and the results are shown as mean ± SD; p<0.05 was considered statistically significant.

Results and Discussion

The 65 participants had normal glucose levels; of them, 25 had high cholesterol levels (≥ 200 mg dl⁻¹= hypercholesterolemic group, HC) and 40 had normal cholesterol levels (< 200 mg dl⁻¹=normocholesterolemic group, NC). As is known, the intestinal microbiota seems to have a clear role in human health [3], and the diet is considered an important factor in its modulation; we didn't find any significant difference in the nutritional and physical activity profile between the study groups. The body mass index (BMI) tended to be higher in the HC group, in which 84% of the participants were overweight or obese, and more than 50% had obesity; in the NC group, 25% had obesity, 40% were overweight, and 35% had normal weight. As can be seen in Table 1, the main differences between groups were determined by the participants with normal weight or obesity. Regarding physical activity, the NC group showed higher physical activity than the HC group (Table 1). Several studies have reported that physical activity, obesity, and diet influence the composition and function of the microbiota [21-23], however, there is still not enough knowledge about the relationship between these factors and the composition and function of microbiota [24]. In this

study, we did not find any differences between groups regarding the consumption of nutrients, although the tendency of the NC group to perform more physical activity implies an increased demand of energy. The intestinal microbiota is involved in several activities, such as energy production, synthesis of micronutrients, fermentation processes and absorption of electrolytes, which regulates both nutrient acquisition and energy extraction through the synthesis of enzymes involved in the metabolism of carbohydrates, cholesterol and proteins [25]. As it was reported in a previous study in rats, both the amount of food consumed and physical activity influence the function and composition of the native microbiota, affecting the host's health [26].

Of all the isolated strains, 247 were identified as non-sporulating bacteria, Gram-positive and negative to catalase and oxidase tests [27]. We determined the sensitivity of the 247 strains to nine antibiotics, setting a threshold for elimination of resistance to 3 or more antibiotics; only the 37.6% of the strains were selected, being sensitive to at least seven antibiotics. The selected strains were identified by partial sequencing of the 16S rRNA ribosomal gene, but only 67 of these sequences were deposited in the Genbank database after several duplicate sequences were identified. Once identified, 49 strains of the *Lactobacillus* and *Enterococcus* genera (Table 2) were selected. Twenty-six strains of the genus *Lactobacillus* and 23 of the genus *Enterococcus* were evaluated, comparing their behavior under different conditions. Seventy-six point nine percent of the *Lactobacillus* strains were isolated from the NC group, while 52.2% of the *Enterococcus* strains were isolated from the HC group; p=0.03 (Figure 1). The ratio between *Lactobacillus* and *Enterococcus* was 1.6 in the NC group and 0.4 in the HC group. Some studies have reported that the proportion of these two genera changes with the presence of Inflammatory Intestinal Disease; these changes were reflected in the depletion of *Lactobacillus* and the increase of *Enterococcus* [28], as we observed in our study, although our participants have hypercholesterolemia, the oxidative stress is the common factor in both cases. In this study, we observed that the

	NC (n = 40)	HC (n = 25)	p	*
Age (years)	34.05 ± 13.40	42.40 ± 10.76	0.008	*
Gender %				
Female, n (%)	(55.00)	(60.00)	0.692	**
Male, n (%)	(45.00)	(40.00)		
BMI (kg/m ²)	27.67 ± 5.90	29.44 ± 4.15	0.195	*
Normal weight	35.00	16.00	0.066	**
Overweight	40.00	32.00		
Obesity	25.00	52.00		
Physical activity				
Low	35.00	40.00	0.902	**
Moderate	32.50	32.00		
High	32.50	28.00		
Biochemicals				
Glucose (mg/dl)	93.30 ± 25.49	94.92 ± 19.49	0.787	*
TC (mg/dl)	163.86 ± 27.72	228.48 ± 23.46	0.000	*
Dietary assessment				
Energy (kcal/d) ^a	2455.21 ± 1111.52	2398.70 ± 930.29	0.832	***
Carbohydrates (g/d) ^{ab}	318.36 ± 162.13	309.10 ± 160.69	0.592	***
Protein (g/d) ^b ^{ab}	83.36 ± 43.60	79.59 ± 21.00	0.458	***
Lipids (g/d) ^{ab}	45.47 ± 25.06	39.09 ± 15.66	0.171	***
Cholesterol (mg/d) ^{ab}	283.23 ± 176.55	273.79 ± 154.36	0.797	***

BMI: Body Mass Index, TC: total cholesterol. *Results from a Student's t test and **Chi-square. Results presented as mean ± standard deviation and percentage. ***General linear model adjusted. for ^a age, gender and ^b energy; Data are presented as mean ± standard deviation.

Table 1: General characteristic of the study groups.

Identified strain	Genbank access	Origin
<i>Lactobacillus</i> sp strain L101(LBF2)E04	KM269715	NC
<i>Lactobacillus</i> sp strain L112(LBF2)F03	KM269716	NC
<i>Lactobacillus</i> sp strain L238(LBF2)G05	KM269717	NC
<i>Lactobacillus</i> sp strain L314(LBF2)H05	KM269718	NC
<i>Lactobacillus</i> sp strain L319(LBF2)C02	KM269719	NC
<i>Lactobacillus</i> sp strain L329(LBF2)D02	KM269720	NC
<i>Lactobacillus plantarum</i> strain A05_0330_01	KP340446	NC
<i>Lactobacillus fermentum</i> strain L634(LBF2)G03	KM269711	NC
<i>Lactobacillus</i> sp strain L656(LBF2)H03	KM269710	HC
<i>Lactobacillus</i> sp strain L729(LBF2)C04	KM269721	NC
<i>Lactobacillus plantarum</i> strain 793_E01	KP178096	NC
<i>Lactobacillus plantarum</i> strain 820_H01	KP178097	HC
<i>Lactobacillus plantarum</i> strain 821_A01	KP178098	HC
<i>Lactobacillus plantarum</i> strain D05_0854_04	KP340447	HC
<i>Lactobacillus plantarum</i> strain 857_C02	KP178099	HC
<i>Lactobacillus plantarum</i> strain 904_D02	KP178100	NC
<i>Lactobacillus</i> sp strain 906_E02	KP178101	NC
<i>Lactobacillus casei</i> strain 1070_A04	KP178092	NC
<i>Lactobacillus</i> sp strain 1265(LBF2)A03	KM269704	NC
<i>Lactobacillus</i> sp strain 1266(BF2)B03	KM269705	NC
<i>Lactobacillus</i> sp strain 1280(LBF2)G02	KM269706	HC
<i>Lactobacillus ruminis</i> strain 1291(LBF2)H05	KM269714	NC
<i>Lactobacillus ruminis</i> strain 1292_G05	KP178094	NC
<i>Lactobacillus</i> sp strain 1311_H05	KP178109	NC
<i>Lactobacillus ruminis</i> strain 1313_A06	KP178095	NC
<i>Lactobacillus plantarum</i> strain B08_1534_02	KP340448	NC
<i>Enterococcus faecium</i> strain L030(LBF2)D03	KM269699	NC
<i>Enterococcus durans</i> strain L106(LBF2)E03	KM269697	HC
<i>Enterococcus faecium</i> strain L175(LBF2)F04	KM269700	HC
<i>Enterococcus faecium</i> strain L179(LBF2)G04	KM269701	HC
<i>Enterococcus faecium</i> strain L180(LBF2)H04	KM269702	HC
<i>Enterococcus faecalis</i> strain B04_0182_02	KP340440	HC
<i>Enterococcus durans</i> strain L186(LBF2)A05	KM269698	HC
<i>Enterococcus</i> sp strain C04_0189_03	KP340441	NC
<i>Enterococcus hirae</i> strain L217(LBF2)C05	KM269707	HC
<i>Enterococcus hirae</i> strain L220(LBF2)D05	KM269708	HC
<i>Enterococcus hirae</i> strain L222(LBF2)E05	KM269709	HC
<i>Enterococcus faecium</i> strain 344(F)_E02	KP178084	NC
<i>Enterococcus</i> sp strain 347_D01	KP178087	NC
<i>Enterococcus faecium</i> strain L703(LBF2)A04	KM269703	HC
<i>Enterococcus durans</i> strain 794_F01	KP178088	NC
<i>Enterococcus faecium</i> strain 855_E03	KP178089	HC
<i>Enterococcus</i> sp strain 919_B01	KP178108	NC
<i>Enterococcus</i> sp strain 1284_F05	KP178106	HC
<i>Enterococcus hirae</i> strain C07_1387_03	KP340442	NC
<i>Enterococcus faecium</i> strain 1479_C05	KP178085	NC
<i>Enterococcus durans</i> strain 1520_D05	KP178086	NC
<i>Enterococcus faecium</i> strain A09_1535_01	KP340439	NC
<i>Enterococcus</i> sp strain 1547_E05	KP178107	NC

Table 2: Strains identified by 16S rRNA sequencing, Genbank access and origin.

participants with obesity and high cholesterol levels had a reduced population of beneficial *Lactobacillus*. The *Lactobacillus* genus has been identified as one of the most beneficial to human health [29]; it has the highest number of strains with probiotic properties. Although some strains of the genus *Enterococcus* have been associated with infectious processes [30], others have shown probiotic properties [29]. Given the functional importance of both genera, we evaluated their behavior in different conditions in order to further our knowledge about the




Figure 1: Distribution of *Lactobacillus* and *Enterococcus* by origin. NC; normocholesterolemic group, HC; hypercholesterolemic group. Black bars, *Lactobacillus*, gray bars, *Enterococcus*.

beneficial functions of the native microbiota. An important function of the native microbiota is its contribution to cholesterol metabolism, mainly of exogenous cholesterol (diet); importantly, we did not find any significant differences in the consumption of cholesterol or any other kind of lipids between the NC and HC groups, which reinforce the idea that the observed differences in the microbiota between the study groups was not due to the consumption of cholesterol or lipids. We observed that *Lactobacillus* has a greater capacity to reduce cholesterol; while *Enterococcus* can also reduce cholesterol, it has a lower activity than *Lactobacillus*. However, the cholesterol-reducing ability of the *Lactobacillus* strains isolated from the HC group was lower than the ability of *Lactobacillus* strains isolated from the NC group. Similar changes in the proportions of *Lactobacillus* and *Enterococcus* strains were reported in a study conducted in rats subjected to changes in diet and physical activity; in that study, the population of *Lactobacillus* was higher in rats that performed physical activity and were fed an ad libitum diet, while the population of *Enterococcus* was higher in rats without physical activity and with induced anorexia [26]. One of the proposed mechanisms to reduce cholesterol involves bile salt hydrolase (BSH), an enzyme produced by bacteria. According to our results, with the exception of four strains, all strains showed hydrolase activity; however, all strains reduced cholesterol after 20 h, independently from the presence of this enzyme, including those strains that did not show hydrolase activity, which means that the mechanism by which these strains reduce cholesterol may not be related only to the enzyme. At the genus level, the average cholesterol reduction rate was 56% for *Lactobacillus* and 51.3% for *Enterococcus*. Analyzing the behavior of the strains according to their origin some differences were observed; the cholesterol reduction rates of *Lactobacillus* (60.5%) and *Enterococcus* (58.2%) strains isolated from the NC group were higher than the rates observed in the strains isolated from the HC group, which were 50.4% and 44.9%, respectively. This shows that *Lactobacillus* is more efficient than *Enterococcus* in cholesterol reduction. Thus, the restoration of the microbiota could be an alternative for the control of total cholesterol levels and other related lipids such as triglycerides, LDL, VLDL, and HDL, independently of the mechanism used [29].

Several studies have reported that *Lactobacillus* and *Enterococcus* strains present resistance to one or more antibiotics, which may be

intrinsic or acquired. *Lactobacilli* have intrinsic resistance to a wide range of antibiotics; however, in the majority of cases, this resistance is non-transferable [31]. These genera are usually sensitive to penicillin, which inhibits the synthesis of the cell wall, as well as to protein synthesis inhibitors such as chloramphenicol, tetracycline and clindamycin [32], which is consistent with the results obtained in this study (Figure 2), in which the sensitivity to penicillin, chloramphenicol and tetracycline was close to 100%, in the case of clindamycin; the 84.6% of the *Lactobacillus* strains were identified as sensitive and the 15.4% was identified as having intermediate sensitivity, and 83% of *Enterococcus* strains were sensitive and 13% were resistant. It has been reported that this genus has an intrinsic resistance to this antibiotic; it could even be considered as a low resistance rate [33]. The sensitivity of *Lactobacillus* strains to Gentamicin was 92.3%, which was also in accordance with previous reports [34], while for *Enterococcus* it was 69.6%, with some strains showing intermediate sensitivity and resistance [33]. In general, the behavior exhibited by the strains in the presence of most antibiotics agrees with that reported in previous studies [35]. The behavior of both genera in the presence of Neomycin was interesting; as can be seen in Figure 3, 3.8% of the *Lactobacillus* strains were resistant to this antibiotic, while the resistance of *Enterococcus* was 8.7%. These rates

of resistance are relatively low, since high rates of resistance have been previously reported for *Lactobacillus* [36] and *Enterococcus* [37], and these genera have an intrinsic resistance to aminoglycosides, to which neomycin belongs. Although in our results the resistance rates were low, there were also a high percentage of intermediate sensitivity strains in both genera, which may tend towards resistance due to the nature of the bacteria. Finally, when evaluating the survival of the strains at acid pH (2.0 and 3.0), and in the presence of bile salts (0.3% w/v), after 3 h in the medium adjusted to pH 2.0, *Lactobacillus* showed a survival rate of 80.8% and *Enterococcus* 87.0%; interestingly, after 24 h under the same conditions, 73.1% of the *Lactobacillus* strains and 34.8% of the *Enterococcus* strains remained viable; it was under these conditions and after 24 h that we found a difference in survival between the genera. At pH 3.0, the survival of *Lactobacillus* (93%) and *Enterococcus* (95.7%) strains after 24 h was very similar, as can be seen, while after 24 h in the MRS medium supplemented with bile salts the survival rates were 96% and 100%, respectively (Figure 3). It is important to consider that the survival rate of bacteria is usually evaluated after 3 h; in this study, we also evaluated it at 24 h, and found a good survival rate at pH 3.0 in bile salts. These results allow us to infer that bacteria can remain in the gastrointestinal tract despite several changes in their environmental. *Lactobacillus* and *Enterococcus* belong to the group of lactic acid bacteria; both perform similar functions, as was appreciated in this study, however when some diseases as hypercholesterolemia occurs, the *Lactobacillus* population decreases causing changes in the gastrointestinal environment which can be one of the main causes of the imbalance in the microbiota, although the population of *Enterococcus* remains constant.

Acknowledgements

This work was supported by Fondos Mixtos del Estado de Guanajuato, Grant GTO 2011-CO4-167944. Claudia Gomez wishes to thank CONACYT for scholarship No. 291204.

References

- Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 124: 837-848.
- Fujimura KE, Slusher NA, Cabana MD, Lynch SV (2010) Role of the gut microbiota in defining human health. *Expert Rev Anti Infect Ther* 8: 435-454.
- Sekirov I, Russell SL, Antunes LC, Finlay BB (2010) Gut microbiota in health and disease. *Physiol Rev* 90: 859-904.
- Marteau P, Pochart P, Doré J, Béra-Maillet C, Bernalier A, et al. (2001) Comparative study of bacterial groups within the human cecal and fecal microbiota. *Appl Environ Microbiol* 67: 4939-4942.
- Lebreton F, Willems RJL, Gilmore MS (2014) *Enterococcus* Diversity, Origins in Nature, and Gut Colonization. (In Gilmore MS, Clewell DB, Ike Y, et al., editors) *Enterococci: from commensals to leading causes of drug resistant infection*. Boston Massachusetts, Eye and Ear Infirmary.
- Klingspor S, Bondzio A, Martens H, Aschenbach JR, Bratz K, et al. (2015) *Enterococcus faecium* NCIMB 10415 modulates epithelial integrity, heat shock protein, and proinflammatory cytokine response in intestinal cells. *Mediators Inflamm* 2015: 304149.
- Roselino MN, Pauly-Silveira ND, Cavallini DC, Celiberto LS, Pinto RA, et al. (2012) A potential synbiotic product improves the lipid profile of diabetic rats. *Lipids Health Dis* 11: 114.
- Bosch M, Fuentes MC, Audivert S, Bonachera MA, Peiró S, et al. (2014) *Lactobacillus plantarum* CECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. *J Sci Food Agric* 94: 803-809.
- Liong MT, Shah NP (2005) Bile salt deconjugation ability, bile salt hydrolase activity cholesterol co-precipitation ability of lactobacilli strains. *Int Dairy J* 15: 391-398.
- Lye HS, Rusul G, Liong MT (2010) Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. *J Dairy Sci* 93: 1383-1392.




Figure 2: Rates of antibiotic susceptibility of *Lactobacillus* (gray bars) and *Enterococcus* (black bars). S= Sensitive; I= Intermediate sensitivity; R= Resistant. Amp= Ampicillin, Gen= Gentamicin, Chlo= Chloramphenicol, Str= Streptomycin, Neo= Neomycin, Ery= Erythromycin, Clin= Clindamycin, Tet= Tetracycline, Kan= Kanamycin.




Figure 3: Survival rates of *Lactobacillus* (gray bars) and *Enterococcus* (black bars) under three different conditions (pH 2.0, pH 3.0, 0.3% bile salts) and times.

11. Öner Ö, Aslim B, Aydaş SB (2014) Mechanisms of cholesterol-lowering effects of lactobacilli and bifidobacteria strains as potential probiotics with their bsh gene analysis. *J Mol Microbiol Biotechnol* 24: 12-18.
12. Agerbaek M, Gerdes LU, Richelsen B (1995) Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. *Eur J Clin Nutr* 49: 346-352.
13. Hlivak P, Odraska J, Ferencik M, Ebringer L, Jahnova E, et al. (2005) One-year application of probiotic strain *Enterococcus faecium* M-74 decreases serum cholesterol levels. *Bratisl Lek Listy* 106: 67-72.
14. Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol* 35: 1-10.
15. Tompkins R, Schwartzbard A, Gianos E, Fisher E, Weintraub H (2014) A current approach to statin intolerance. *Clin Pharmacol Ther* 96: 74-80.
16. Shi M, Zheng H, Nie B, Gong W, Cui X (2014) Statin use and risk of liver cancer: an update meta-analysis. *BMJ Open* 4: e005399.
17. Martínez-González MA, López-Fontana C, Varo JJ, Sánchez-Villegas A, Martínez JA (2005) Validation of the Spanish version of the physical activity questionnaire used in the Nurses' Health Study and the Health Professionals' Follow-up Study. *Public Health Nutr* 8: 920-927.
18. CLSI (2013) Performance Standards for Antimicrobial Susceptibility Testing. 23th Informational Supplement Clinical and Laboratory Standards Institute document, Wayne, PA, M100-S23.
19. Bao Y, Zhang Y, Zhang Y, Liu Y, Wang S, et al. (2010) Screening of potential probiotic properties of *Lactobacillus fermentum* isolated from traditional dairy products. *Food Control* 21: 695-701.
20. Vancanneyt M, Mengaud J, Cleenwerck I, Vanhonacker K, Hoste B, et al. (2004) Reclassification of *Lactobacillus kefirgranum* Takizawa et al. 1994 as *Lactobacillus kefiranoferiens* subsp. *kefirgranum* subsp. nov. and emended description of *L. kefiranoferiens* Fujisawa et al. 1988. *Int J Syst Evol Microbiol* 54: 551-556.
21. O'Sullivan O, Cronin O, Clarke SF, Murphy EF, Molloy MG, et al. (2015) Exercise and the microbiota. *Gut Microbes* 6: 131-136.
22. Petriz BA, Castro AP, Almeida JA, Gomes CP, Fernandes GR, et al. (2014) Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats. *BMC Genomics* 15: 511.
23. Hold GL (2014) The gut microbiota, dietary extremes and exercise. *Gut* 63: 1838-1839.
24. Gerritsen J, Smidt H, Rijkers GT, de Vos WM (2011) Intestinal microbiota in human health and disease: the impact of probiotics. *Genes Nutr* 6: 209-240.
25. Tehrani AB, Nezami BG, Gewirtz A, Srinivasan S (2012) Obesity and its associated disease: a role for microbiota? *Neurogastroenterol Motil* 24: 305-311.
26. Queipo-Ortuno MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, et al. (2013) Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. *PLoS One* 8: e65465.
27. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, et al. (2001) In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. *Am J Clin Nutr* 73: 386S-392S.
28. Zhang T, Chen Y, Wang Z, Zhou Y, Zhang S, et al. (2013) Changes of fecal flora and its correlation with inflammatory indicators in patients with inflammatory bowel disease. *Nan Fang Yi Ke Da Xue Xue Bao* 33: 1474-1477.
29. Fijan S (2014) Microorganisms with claimed probiotic properties: an overview of recent literature. *Int J Environ Res Public Health* 11: 4745-4767.
30. Jett BD, Huycke MM, Gilmore MS (1994) Virulence of enterococci. *Clin Microbiol Rev* 7: 462-478.
31. Ashraf R, Shah NP (2011) Antibiotic resistance of probiotic organisms and safety of probiotic dairy products. *Int Food Res J* 18: 837-853.
32. Gueimonde M, Sánchez B, G de Los Reyes-Gavilán C, Margolles A (2013) Antibiotic resistance in probiotic bacteria. *Front Microbiol* 4: 202.
33. Torres C, Cercenado E (2010) Interpretive reading of the antibiogram in gram positive cocci. *Enferm Infecc Microbiol Clin* 28: 541-553.
34. Liasi SA, Azmi TI, Hassan MD, Shuhaimi M, Rosfarizan M, et al. (2009) Antimicrobial activity and antibiotic sensitivity of three isolates of lactic acid bacteria from fermented fish product, Budu. *Mal J Microbiol* 5: 33-37.
35. Fukao M, Yajima N (2012) Assessment of antibiotic resistance in probiotic lactobacilli. In: InTechopen, editor. Antibiotic resistant bacteria - A continuous challenge in the new millennium. Rijeka, Croatia. pp: 503-512.
36. Zhou JS, Pillidge CJ, Gopal PK, Gill HS (2005) Antibiotic susceptibility profiles of new probiotic *Lactobacillus* and *Bifidobacterium* strains. *Int J Food Microbiol* 98: 211-217.
37. Bourouni OC, El Bour M, Calo-Mata P, Barros-Velazquez J (2012) Antimicrobial resistance and potential probiotic application of *Enterococcus* spp. in sea bass and sea bream aquaculture. In: Pana M, editor. Antibiotic resistant bacteria. A continuous challenge in the new millennium InTech. pp: 513-530.